XLO - Xilio to Host Virtual Investor Conference Call and Webcast on Monday November 6 2023 to Review Progress Across Pipeline Including Phase 1/2 Clinical Data for XTX202 a Tumor-Activated Engineered Beta-Gamma IL-2 Presented at the SITC Annual Meeting |
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023.
The call will feature members of Xilio's management team and Howard Kaufman, M.D., FACS, a clinical investigator on Xilio's Phase 1/2 clinical trial for XTX202 and a leading authority of local tumor immunotherapy and oncolytic viruses.
Conference Call and Webcast Information
The webcast may be accessed by clicking here. The webcast of the conference call will also be available under "Events and Presentations" in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. The archived webcast will be available on the Xilio Therapeutics website approximately two hours after the conference call and will be available for 30 days following the call.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, ...